Table 1.
Baseline characteristics of the patients
| Variable | Mild RV dysfunction (n=42) | Moderate RV dysfunction (n=21) | Severe RV dysfunction (n=47) | P value |
|---|---|---|---|---|
| Age, years | 62.86±13.34 | 58.19±15.60 | 41.47±16 | <0.001 |
| Gender, n (%) | 0.001 | |||
| Male | 26(61.90) | 10 (47.60) | 11 (23.40) | |
| Female | 16(38.10) | 11 (52.40) | 36 (76.60) | |
| WHO FC, n (%) | <0.001 | |||
| I | 16 (38.10) | 0 (0) | 0 | |
| II | 24 (47.10) | 1 (4.80) | 0 | |
| III | 2 (4.80) | 18 (85.70) | 9 (19.10) | |
| IV | 0 (0) | 2 (9.50) | 38 (80.90) | |
| Cause | <0.001 | |||
| IPAH | 7(16.70) | 5(23.80) | 33(70.20) | |
| CTEPH | 7(16.70) | 4(19.05) | 9(19.10) | |
| Connective tissue disease | 8(19.05) | 3(14.30) | 2(4.30) | |
| Sarcoidosis | 9(21.40) | 4(19.05) | 0 | |
| Asthma | 11(26.20) | 5(23.80) | 0 | |
| PVOD | 0 | 0 | 2(4.30) | |
| Thalassemia | 0 | 0 | 1(2.10) | |
| Pulmonary artery systolic pressure, mmHg* | 40 (35–50) | 55 (42.50–70) | 80 (75–95) | <0.001 |
| Uric acid, mg/dl* | 4.70 (3.87–5.82) | 5 (3.50–6.95) | 7.80 (5.80–9.20) | <0.001 |
*
Data expressed as median (IQR)
WHO FC: WHO functional class; IPAH: Idiopathic Pulmonary Arterial Hypertension; CTEPH: Chronic Thromboembolic Pulmonary Hypertension; PVOD: Pulmonary Veno-Occlusive Disease